Parkinsonian syndrome after long-term treatment with clebopride
Identifieur interne :
003859 ( PascalFrancis/Corpus );
précédent :
003858;
suivant :
003860
Parkinsonian syndrome after long-term treatment with clebopride
Auteurs : P. Montagna ;
A. S. Gabellini ;
L. Monari ;
E. LugaresiSource :
-
Movement disorders [ 0885-3185 ] ; 1992.
RBID : Pascal:92-0289118
Descripteurs français
English descriptors
Notice en format standard (ISO 2709)
Pour connaître la documentation sur le format Inist Standard.
pA |
A01 | 01 | 1 | | @0 0885-3185 |
---|
A03 | | 1 | | @0 Mov. disord. |
---|
A05 | | | | @2 7 |
---|
A06 | | | | @2 1 |
---|
A08 | 01 | 1 | ENG | @1 Parkinsonian syndrome after long-term treatment with clebopride |
---|
A11 | 01 | 1 | | @1 MONTAGNA (P.) |
---|
A11 | 02 | 1 | | @1 GABELLINI (A. S.) |
---|
A11 | 03 | 1 | | @1 MONARI (L.) |
---|
A11 | 04 | 1 | | @1 LUGARESI (E.) |
---|
A14 | 01 | | | @1 Inst. neurology @2 40123 Bologna @3 ITA |
---|
A20 | | | | @1 89-90 |
---|
A21 | | | | @1 1992 |
---|
A23 | 01 | | | @0 ENG |
---|
A43 | 01 | | | @1 INIST @2 20953 @5 354000023029590180 |
---|
A44 | | | | @0 0000 |
---|
A45 | | | | @0 9 ref. |
---|
A47 | 01 | 1 | | @0 92-0289118 |
---|
A60 | | | | @1 P @3 CC |
---|
A61 | | | | @0 A |
---|
A64 | | 1 | | @0 Movement disorders |
---|
A66 | 01 | | | @0 USA |
---|
C02 | 01 | X | | @0 002B02U01 |
---|
C03 | 01 | X | FRE | @0 Toxicité |
---|
C03 | 01 | X | ENG | @0 Toxicity |
---|
C03 | 01 | X | GER | @0 Giftigkeit |
---|
C03 | 01 | X | SPA | @0 Toxicidad |
---|
C03 | 02 | X | FRE | @0 Homme |
---|
C03 | 02 | X | ENG | @0 Human |
---|
C03 | 02 | X | SPA | @0 Hombre |
---|
C03 | 03 | X | FRE | @0 Etude cas |
---|
C03 | 03 | X | ENG | @0 Case study |
---|
C03 | 03 | X | SPA | @0 Estudio caso |
---|
C03 | 04 | X | FRE | @0 Long terme |
---|
C03 | 04 | X | ENG | @0 Long term |
---|
C03 | 04 | X | SPA | @0 Largo plazo |
---|
C03 | 05 | X | FRE | @0 Clébopride @2 NK @2 FR |
---|
C03 | 06 | X | FRE | @0 Antiémétique |
---|
C03 | 06 | X | ENG | @0 Antiemetic |
---|
C03 | 06 | X | SPA | @0 Antiemético |
---|
C03 | 07 | X | FRE | @0 Récepteur dopaminergique D2 |
---|
C03 | 07 | X | ENG | @0 D2 Dopamine receptor @6 «D2» Dopamine receptor |
---|
C03 | 07 | X | SPA | @0 Receptor dopaminérgico D2 |
---|
C03 | 08 | X | FRE | @0 Antagoniste dopamine |
---|
C03 | 08 | X | ENG | @0 Dopamine antagonist |
---|
C03 | 08 | X | SPA | @0 Antagonista dopamina |
---|
C07 | 01 | X | FRE | @0 Extrapyramidal syndrome |
---|
C07 | 01 | X | ENG | @0 Extrapyramidal syndrome |
---|
C07 | 01 | X | SPA | @0 Extrapiramidal síndrome |
---|
C07 | 02 | X | FRE | @0 Système nerveux pathologie |
---|
C07 | 02 | X | ENG | @0 Nervous system diseases |
---|
C07 | 02 | X | SPA | @0 Sistema nervioso patología |
---|
N21 | | | | @1 198 |
---|
|
Format Inist (serveur)
NO : | PASCAL 92-0289118 INIST |
ET : | Parkinsonian syndrome after long-term treatment with clebopride |
AU : | MONTAGNA (P.); GABELLINI (A. S.); MONARI (L.); LUGARESI (E.) |
AF : | Inst. neurology/40123 Bologna/Italie |
DT : | Publication en série; Courte communication, note brève; Niveau analytique |
SO : | Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 1992; Vol. 7; No. 1; Pp. 89-90; Bibl. 9 ref. |
LA : | Anglais |
CC : | 002B02U01 |
FD : | Toxicité; Homme; Etude cas; Long terme; Clébopride; Antiémétique; Récepteur dopaminergique D2; Antagoniste dopamine |
FG : | Extrapyramidal syndrome; Système nerveux pathologie |
ED : | Toxicity; Human; Case study; Long term; Antiemetic; D2 Dopamine receptor; Dopamine antagonist |
EG : | Extrapyramidal syndrome; Nervous system diseases |
GD : | Giftigkeit |
SD : | Toxicidad; Hombre; Estudio caso; Largo plazo; Antiemético; Receptor dopaminérgico D2; Antagonista dopamina |
LO : | INIST-20953.354000023029590180 |
ID : | 92-0289118 |
Links to Exploration step
Pascal:92-0289118
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Parkinsonian syndrome after long-term treatment with clebopride</title>
<author><name sortKey="Montagna, P" sort="Montagna, P" uniqKey="Montagna P" first="P." last="Montagna">P. Montagna</name>
<affiliation><inist:fA14 i1="01"><s1>Inst. neurology</s1>
<s2>40123 Bologna</s2>
<s3>ITA</s3>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gabellini, A S" sort="Gabellini, A S" uniqKey="Gabellini A" first="A. S." last="Gabellini">A. S. Gabellini</name>
</author>
<author><name sortKey="Monari, L" sort="Monari, L" uniqKey="Monari L" first="L." last="Monari">L. Monari</name>
</author>
<author><name sortKey="Lugaresi, E" sort="Lugaresi, E" uniqKey="Lugaresi E" first="E." last="Lugaresi">E. Lugaresi</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">92-0289118</idno>
<date when="1992">1992</date>
<idno type="stanalyst">PASCAL 92-0289118 INIST</idno>
<idno type="RBID">Pascal:92-0289118</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">003859</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Parkinsonian syndrome after long-term treatment with clebopride</title>
<author><name sortKey="Montagna, P" sort="Montagna, P" uniqKey="Montagna P" first="P." last="Montagna">P. Montagna</name>
<affiliation><inist:fA14 i1="01"><s1>Inst. neurology</s1>
<s2>40123 Bologna</s2>
<s3>ITA</s3>
</inist:fA14>
</affiliation>
</author>
<author><name sortKey="Gabellini, A S" sort="Gabellini, A S" uniqKey="Gabellini A" first="A. S." last="Gabellini">A. S. Gabellini</name>
</author>
<author><name sortKey="Monari, L" sort="Monari, L" uniqKey="Monari L" first="L." last="Monari">L. Monari</name>
</author>
<author><name sortKey="Lugaresi, E" sort="Lugaresi, E" uniqKey="Lugaresi E" first="E." last="Lugaresi">E. Lugaresi</name>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="1992">1992</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antiemetic</term>
<term>Case study</term>
<term>D2 Dopamine receptor</term>
<term>Dopamine antagonist</term>
<term>Human</term>
<term>Long term</term>
<term>Toxicity</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Toxicité</term>
<term>Homme</term>
<term>Etude cas</term>
<term>Long terme</term>
<term>Clébopride</term>
<term>Antiémétique</term>
<term>Récepteur dopaminergique D2</term>
<term>Antagoniste dopamine</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA08 i1="01" i2="1" l="ENG"><s1>Parkinsonian syndrome after long-term treatment with clebopride</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>MONTAGNA (P.)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>GABELLINI (A. S.)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>MONARI (L.)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>LUGARESI (E.)</s1>
</fA11>
<fA14 i1="01"><s1>Inst. neurology</s1>
<s2>40123 Bologna</s2>
<s3>ITA</s3>
</fA14>
<fA20><s1>89-90</s1>
</fA20>
<fA21><s1>1992</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000023029590180</s5>
</fA43>
<fA44><s0>0000</s0>
</fA44>
<fA45><s0>9 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>92-0289118</s0>
</fA47>
<fA60><s1>P</s1>
<s3>CC</s3>
</fA60>
<fA64 i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC02 i1="01" i2="X"><s0>002B02U01</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Toxicité</s0>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Toxicity</s0>
</fC03>
<fC03 i1="01" i2="X" l="GER"><s0>Giftigkeit</s0>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Toxicidad</s0>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Homme</s0>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Human</s0>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Hombre</s0>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Etude cas</s0>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Case study</s0>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Estudio caso</s0>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Long terme</s0>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Long term</s0>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Largo plazo</s0>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Clébopride</s0>
<s2>NK</s2>
<s2>FR</s2>
</fC03>
<fC03 i1="06" i2="X" l="FRE"><s0>Antiémétique</s0>
</fC03>
<fC03 i1="06" i2="X" l="ENG"><s0>Antiemetic</s0>
</fC03>
<fC03 i1="06" i2="X" l="SPA"><s0>Antiemético</s0>
</fC03>
<fC03 i1="07" i2="X" l="FRE"><s0>Récepteur dopaminergique D2</s0>
</fC03>
<fC03 i1="07" i2="X" l="ENG"><s0>D2 Dopamine receptor</s0>
<s6>«D2» Dopamine receptor</s6>
</fC03>
<fC03 i1="07" i2="X" l="SPA"><s0>Receptor dopaminérgico D2</s0>
</fC03>
<fC03 i1="08" i2="X" l="FRE"><s0>Antagoniste dopamine</s0>
</fC03>
<fC03 i1="08" i2="X" l="ENG"><s0>Dopamine antagonist</s0>
</fC03>
<fC03 i1="08" i2="X" l="SPA"><s0>Antagonista dopamina</s0>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Extrapyramidal syndrome</s0>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Système nerveux pathologie</s0>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Nervous system diseases</s0>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
</fC07>
<fN21><s1>198</s1>
</fN21>
</pA>
</standard>
<server><NO>PASCAL 92-0289118 INIST</NO>
<ET>Parkinsonian syndrome after long-term treatment with clebopride</ET>
<AU>MONTAGNA (P.); GABELLINI (A. S.); MONARI (L.); LUGARESI (E.)</AU>
<AF>Inst. neurology/40123 Bologna/Italie</AF>
<DT>Publication en série; Courte communication, note brève; Niveau analytique</DT>
<SO>Movement disorders; ISSN 0885-3185; Etats-Unis; Da. 1992; Vol. 7; No. 1; Pp. 89-90; Bibl. 9 ref.</SO>
<LA>Anglais</LA>
<CC>002B02U01</CC>
<FD>Toxicité; Homme; Etude cas; Long terme; Clébopride; Antiémétique; Récepteur dopaminergique D2; Antagoniste dopamine</FD>
<FG>Extrapyramidal syndrome; Système nerveux pathologie</FG>
<ED>Toxicity; Human; Case study; Long term; Antiemetic; D2 Dopamine receptor; Dopamine antagonist</ED>
<EG>Extrapyramidal syndrome; Nervous system diseases</EG>
<GD>Giftigkeit</GD>
<SD>Toxicidad; Hombre; Estudio caso; Largo plazo; Antiemético; Receptor dopaminérgico D2; Antagonista dopamina</SD>
<LO>INIST-20953.354000023029590180</LO>
<ID>92-0289118</ID>
</server>
</inist>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003859 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Corpus/biblio.hfd -nk 003859 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= PascalFrancis
|étape= Corpus
|type= RBID
|clé= Pascal:92-0289118
|texte= Parkinsonian syndrome after long-term treatment with clebopride
}}
| This area was generated with Dilib version V0.6.23. Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024 | |